like others, Collie puzzles me. Firstly it was maintain the $5.40 target, then a further downgrade!! And the ph 3 is going ahead. Plus shortly anns re spinal applications, lumbar plus diabetes? Or are we a one trick pony? I'd advise that all holders keep writing to ASIC and the ASX to clarify the short selling and associated trading. I think that the identities of shorters should be information freely available to all the market. And not just the nominee companies. This carp has gone on for too long. How is it that short position reduces by half with nothing like those numbers traded? It's garbage and it's undermining the integrity of the market. Meanwhile, MSB will hopefully derisk by aligning with another BP rather than relying on Teva. We ARE more than a one trick pony, which MSB in the next 2 months will illustrate graphically
MSB Price at posting:
$5.92 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)